Results 71 to 80 of about 5,814 (191)

Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami, Yukari Okubo, Satomi Kobayashi, Natsuko Kikuta, Yoshiumi Ouchi, Kenta Shishido, Tadashi Terui   +6 more
wiley   +1 more source

Annular pustular crusted plaques as unusual cutaneous presentation of systemic lupus erythematosus

Clinical Case Reports, 2023
Key Clinical Message Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that affects several organs including the skin. Clinical cutaneous symptoms of SLE come in a broad range, consisting of both non‐specific and specific cutaneous ...
Mehdi Gheisari, Moein Baghani, Raziyeh Ganji, Khatere Zahedi   +3 more
doaj   +1 more source

Practical dermatology [PDF]

, 2006
DERMATOLOGYSKIN DISEASESКОЖНЫЕ БОЛЕЗНИМЕТОДИЧЕСКИЕ РЕКОМЕНДАЦИИПРАКТИЧЕСКАЯ ДЕРМАТОЛОГИЯRecommendations include tests, clinical tasks and practical skills in dermatology that are used as during practical classes as at the ...
Adaskevich, V. P., Katina, M. A., Valles-Kazlouskaya, V. V.   +2 more
core  

Dermatology 2.0: Precision medicine for inflammatory skin diseases

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Digital immune mapping of transcriptomics profiles from inflammatory skin disease biopsies enables precise molecular diagnosis, quantification of immune modules and personalized therapy selection by matching dominant immune signatures to targeted treatments.
Jeremy Di Domizio, Antoine Girardin, Curdin Conrad, Teofila Seremet, Michel Gilliet   +4 more
wiley   +1 more source

Síndrome de Reiter exacerbado por indometacina [PDF]

, 1989
A 26-year-old man, with a personal history of drug abuse and positive serology for HIV, had Reiter's syndrome for six years. He experienced progressive worsening of his cutaneous lesions after initiation of indomethacin therapy.
Allegue, F. (F.), Boixeda, P. (Pablo), España, A. (Agustín), Ledo, A. (Antonio), Moreno, R. (R.)   +4 more
core  

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

Journal of the European Academy of Dermatology and Venereology, EarlyView.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault, Emilie Brenaut, Marie‐Emeline Marniquet, Carla Berthault, Lea Canoen, Clarisse Marcombes, Audrey Melin, Raphaël Ouakrat, Julie Charles, Stephane Mouret, Olivier Potie, Laetitia Penso, Laura Pina Vegas, Guillaume Larid, Marine Roux, Colombe Bougeard, Sandy Sylvain, Clara Labonne, Tania Randriamiarana, Da Hee Pitaud, Floriane Etheve, Jeremy Gottlieb, Laurie Gouillon, Marine Chastagner, Emilie Sbidian, Hélène Aubert, on behalf of the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), Hélène Aubert, Marie Masson Regnault, Emilie Brenaut, Emilie Sbidian, Laura Pina Vegas, Laetitia Penso, Jeremy Gottlieb, Marine Roux, Clara Labonne, Tania Randriamiarana, Floriane Etheve, Da Hee Pitaud, Marie‐Emeline Marniquet, Carla Berthault, Clarisse Marcombes, Audrey Melin, Colombe Bougeard, Julie Charles, Olivier Potie, Léa Canoen, Laurie Gouillon, Marine Chastagner, Sandy Sylvain, Guillaume Larid, Raphaël Ouakrat   +51 more
wiley   +1 more source

Limited Contribution of IL-36 versus IL-1 and TNF Pathways in Host Response to Mycobacterial Infection [PDF]

, 2015
IL-36 cytokines are members of the IL-1 family of cytokines that stimulate dendritic cells and T cells leading to enhanced T helper 1 responses in vitro and in vivo ; however, their role in host defense has not been fully addressed thus far.
Segueni, Noria, Vigne, Solenne, Palmer, Gaby, Bourigault, Marie-Laure, Olleros, Maria L., Vesin, Dominique, Garcia, Irene, Ryffel, Bernhard, Quesniaux, Valérie F. J., Gabay, Cem   +9 more
core   +1 more source

Erythrokeratodermia‐Cardiomyopathy Syndrome: Expanding the DSP Mutational Spectrum Beyond Proline Substitutions

Pediatric Dermatology, EarlyView.
ABSTRACT Erythrokeratodermia cardiomyopathy (EKC) syndrome is a rare autosomal dominant disorder characterized by generalized erythrokeratoderma and progressive dilated cardiomyopathy, caused by pathogenic variants in the SR6 domain of desmoplakin (DSP).
Sepideh Hamzehlou, Ryland D. Mortlock, Caroline Echeandia‐Francis, Jing Zhou, Chao Xing, Nnenna G. Agim, Keith A. Choate, Donald A. Glass II   +7 more
wiley   +1 more source

Generalized Pustular Psoriasis [PDF]

The Journal of Pediatrics, 2017
Hideyuki Kosumi, Takamasa Ito, Yasuyuki Fujita, Kentaro Izumi, Yuka Maya, Teruki Yanagi, Ken Natsuga, Hideyuki Ujiie, Satoru Shinkuma, Toshifumi Nomura, Naoya Sadanobu, Hiroshi Shimizu   +11 more
openaire   +3 more sources

Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis. [PDF]

, 2020
Risankizumab-rzaa (Skyrizi®; AbbVie) is a humanized IgG monoclonal antibody directed against interleukin-23p19 (IL-23p19) indicated for the treatment of moderate-to-severe psoriasis in adults who are candidates for systemic therapy or phototherapy.
Liao, Wilson, Myers, Bridget, Reddy, Vidhatha, Yang, Eric J   +3 more
core   +1 more source